Literature DB >> 15564824

Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.

Joseph C Sniezek1, Keith E Matheny, Mathew D Westfall, Jennifer A Pietenpol.   

Abstract

OBJECTIVES/HYPOTHESIS: p63, a member of the p53 family of genes, is vital for normal epithelial development and may play a critical role in epithelial tumor formation. Although p63 has been identified in various head and neck malignancies, a detailed analysis of which of the six isoforms of the p63 gene is present in normal mucosa and head and neck malignancies has not yet been performed. The study analyzed p63 isoform expression on the RNA and protein level in normal, diseased, and malignant mucosa of the head and neck to examine the differential expression of p63 isoforms in head and neck tumors versus adjacent nonmalignant tissue and to identify the predominant p63 isoform expressed in head and neck squamous cell carcinoma (HNSCC). STUDY
DESIGN: Three experiments were performed. In experiment 1, p63 expression was analyzed by immunohistochemical analysis in 36 HNSCC specimens and matched normal tissue control specimens harvested from the same patient. Western blot analysis was also performed on matched specimens to confirm the identity of the p63 isoforms that were found. In experiment 2, reverse transcriptase polymerase chain reaction (RT-PCR) analysis was performed on matched normal and tumor specimens to analyze and quantitatively compare p63 isoform expression at the RNA level. In experiment 3, p63 expression was evaluated by immunohistochemical analysis in oral lichen planus, a benign mucosal lesion marked by hyperdifferentiation and apoptosis.
METHODS: Immunohistochemical analysis, RT-PCR, and Western blot analysis of p63 were performed on HNSCC specimens and matched normal tissue control specimens. p63 expression in oral lichen planus specimens was also examined by immunohistochemical analysis.
RESULTS: In experiment 1, analysis of 36 HNSCC specimens from various head and neck subsites showed p63 expression in all tumors and matched normal tissue specimens (36 of 36). Western blot analyses indicated that dominant negative (DeltaN) isoform p63alpha (DeltaNp63alpha) is the major isoform expressed at the protein level in tumors and adjacent normal tissue. In experiment 2, RT-PCR analyses of 10 matched specimens confirmed that, although all three DeltaNp63 isoforms (DeltaNp63alpha, DeltaNp63beta, and DeltaNp63gamma) are expressed in normal and malignant mucosa of the head and neck, DeltaNp63alpha is the predominant transcript expressed. In experiment 3, immunohistochemical analysis of p63 in the pro-apoptotic condition of lichen planus indicated that p63 is underexpressed as compared with normal mucosal specimens.
CONCLUSION: Although all three DeltaNp63 isoforms are present in HNSCC, DeltaNp63alpha protein is the predominant isoform expressed in these malignancies. DeltaNp63alpha is also overexpressed in tumors compared with matched normal tissue specimens and is underexpressed in the pro-apoptotic condition of lichen planus. These findings suggest that DeltaNp63alpha plays an anti-differentiation and anti-apoptotic role in the mucosal epithelium of the head and neck, possibly playing a pivotal role in the formation of HNSCC. Currently, DeltaNp63alpha is an attractive target for mechanistic study aimed at therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564824     DOI: 10.1097/01.mlg.0000149437.35855.4b

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  50 in total

1.  ΔNp63α regulates keratinocyte proliferation by controlling PTEN expression and localization.

Authors:  M K Leonard; R Kommagani; V Payal; L D Mayo; H N Shamma; M P Kadakia
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

2.  p63 maintains keratinocyte proliferative capacity through regulation of Skp2-p130 levels.

Authors:  Simon S McDade; Daksha Patel; Dennis J McCance
Journal:  J Cell Sci       Date:  2011-04-21       Impact factor: 5.285

3.  Evaluation of p53, p63, p21, p27, ki-67 in paranasal sinus squamous cell carcinoma and inverted papilloma.

Authors:  Semih Oncel; Tulin Cosgul; Aylin Calli; Caglar Calli; Ercan Pinar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-04-11

4.  STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Authors:  Yukihiro Otaka; Susumu Rokudai; Kyoichi Kaira; Michiru Fujieda; Ikuko Horikoshi; Reika Iwakawa-Kawabata; Shinji Yoshiyama; Takehiko Yokobori; Yoichi Ohtaki; Kimihiro Shimizu; Tetsunari Oyama; Jun'ichi Tamura; Carol Prives; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

Review 5.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

6.  Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage.

Authors:  Ramakrishna Kommagani; Vandana Payal; Madhavi P Kadakia
Journal:  J Biol Chem       Date:  2007-08-23       Impact factor: 5.157

7.  NRP-1 interacts with GIPC1 and α6/β4-integrins to increase YAP1/∆Np63α-dependent epidermal cancer stem cell survival.

Authors:  Daniel Grun; Gautam Adhikary; Richard L Eckert
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

Review 8.  The p53 family and programmed cell death.

Authors:  E C Pietsch; S M Sykes; S B McMahon; M E Murphy
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

9.  Transforming growth factor-β1 activates ΔNp63/c-Myc to promote oral squamous cell carcinoma.

Authors:  Lihua Hu; Jingpeng Liu; Zhi Li; Chunling Wang; Ali Nawshad
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2016-06-08

10.  Role of p63 in Development, Tumorigenesis and Cancer Progression.

Authors:  Johann Bergholz; Zhi-Xiong Xiao
Journal:  Cancer Microenviron       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.